Sihuan Pharmaceutical Holdings Group (SEHK:460) - Aandelenkoers, Nieuws & Analyse

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

460 Overzicht aandelen

460 fundamentele analyse
Sneeuwvlok Score
Waardering	0/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	3/6
Dividenden	2/6

Beloningen

De winst is de afgelopen 5 jaar met 13% per jaar gegroeid

Risicoanalyse

Het dividend van 6.45% wordt niet goed gedekt door de winst of de vrije kasstromen

Sihuan Pharmaceutical Holdings Group Ltd. Concurrenten

Shanghai Fudan-Zhangjiang Bio-PharmaceuticalLtd

SEHK:1349

HK$7.5b

Beijing Tong Ren Tang Chinese Medicine

SEHK:3613

HK$8.0b

Consun Pharmaceutical Group

SEHK:1681

HK$6.4b

China Shineway Pharmaceutical Group

SEHK:2877

HK$7.2b

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Sihuan Pharmaceutical Holdings Group
Historische aandelenkoersen
Huidige aandelenkoers	HK$0.72
52 Week Hoogtepunt	HK$0.72
52 Week Laag	HK$0.49
Bèta	0.60
11 maand verandering	30.91%
3 maanden verandering	35.85%
1 Jaar Verandering	20.00%
33 jaar verandering	-54.14%
5 jaar verandering	-36.28%
Verandering sinds IPO	-75.04%

Recent nieuws en updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Oct 02

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Sep 30

Recent updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Oct 02

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Sep 30

Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year

May 31

Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

May 27

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Dec 05

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

Oct 31

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Aug 19

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Apr 21

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Nov 03

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Oct 11

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Jun 21

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Mar 09

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Nov 28

Sihuan Pharmaceutical Holdings Group (HKG:460) Seems To Use Debt Rather Sparingly

Sep 26

We Think Shareholders Are Less Likely To Approve A Large Pay Rise For Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO For Now

Jun 22

How Does Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Fare As A Dividend Stock?

May 11

Sihuan Pharmaceutical Holdings Group's (HKG:460) Shareholders May Want To Dig Deeper Than Statutory Profit

Mar 30

How Much Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Do Insiders Own?

Mar 07

Should You Buy Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) For Its Dividend?

Feb 07

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Jan 11

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Dec 21

Why Sihuan Pharmaceutical Holdings Group's (HKG:460) CEO Pay Matters

Dec 07

Rendement voor aandeelhouders

	460	HK Pharmaceuticals	HK Markt
7D	24.1%	10.3%	9.6%
1Y	20.0%	34.6%	27.2%

Rendement versus industrie: 460 presteerde slechter dan de Hong Kong Pharmaceuticals -sector, die het afgelopen jaar een rendement van 26.7 % opleverde.

Rendement versus markt: 460 presteerde slechter dan Hong Kong Market, dat het afgelopen jaar een rendement van 19.7 % opleverde.

Prijsvolatiliteit

Is 460's price volatile compared to industry and market?
460 volatility
460 Average Weekly Movement	6.0%
Pharmaceuticals Industry Average Movement	5.5%
Market Average Movement	7.9%
10% most volatile stocks in HK Market	17.4%
10% least volatile stocks in HK Market	3.8%

Stabiele aandelenkoers: 460 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: De wekelijkse volatiliteit ( 6% ) van 460 is het afgelopen jaar stabiel geweest.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2001	2,648	Weicheng Guo	www.sihuanpharm.com

Sihuan Pharmaceutical Holdings Group Ltd., een investeringsholding, houdt zich bezig met onderzoek en ontwikkeling, productie, marketing en verkoop van farmaceutische en medisch-esthetische producten in de Volksrepubliek China. Het bedrijf is actief in drie segmenten: Medische Esthetische Producten, Innovatieve Geneeskunde en Andere Geneeskunde, en Generieke Geneeskunde. Het biedt opvulling, vormgeving, ondersteuning, aanvulling, opto-elektronische apparatuur, bodysculpturering, huidverzorging en andere, evenals niet- of minimaal invasieve medische esthetische totaaloplossingen.

Sihuan Pharmaceutical Holdings Group Ltd. Samenvatting

Hoe verhouden de winst en inkomsten van Sihuan Pharmaceutical Holdings Group zich tot de beurswaarde?
460 fundamentele statistieken
Marktkapitalisatie	HK$6.71b
Inkomsten(TTM)	-HK$41.61m
Inkomsten(TTM)	HK$1.93b

3.5x

P/S-verhouding

-161.3x

Koers/Winstverhouding

Is 460 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
460 resultatenrekening (TTM)
Inkomsten	CN¥1.75b
Kosten van inkomsten	CN¥598.10m
Brutowinst	CN¥1.16b
Overige uitgaven	CN¥1.19b
Inkomsten	-CN¥37.80m

Laatst gerapporteerde inkomsten

Jun 30, 2024

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.0041
Brutomarge	65.91%
Nettowinstmarge	-2.15%
Schuld/Eigen Vermogen Verhouding	21.4%

Hoe presteerde 460 op de lange termijn?

Bekijk historische prestaties en vergelijking

Dividenden

5.8%

Huidig dividendrendement

-467%

Uitbetalingsratio

460 Overzicht aandelen

Beloningen

Risicoanalyse

Sihuan Pharmaceutical Holdings Group Ltd. Concurrenten

SEHK:1349

HK$7.5b

SEHK:3613

HK$8.0b

SEHK:1681

HK$6.4b

SEHK:2877

HK$7.2b

Prijsgeschiedenis en prestaties

Recent nieuws en updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Recent updates

What Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 25% Share Price Gain Is Not Telling You

Is Sihuan Pharmaceutical Holdings Group (HKG:460) Using Too Much Debt?

Upcoming dividend of HK$0.021 per share

First half 2024 earnings released: CN¥0.004 loss per share (vs CN¥0.005 loss in 1H 2023)

Sihuan Pharmaceutical Holdings Group Ltd. Announces Interim Ordinary Cash Dividend for the Six Months Ended June 30, 2024, Payable on 10 October 2024

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2024 Results on Aug 30, 2024

Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration

New major risk - Revenue and earnings growth

Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA

Here's Why It's Unlikely That Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) CEO Will See A Pay Rise This Year

Investors Still Waiting For A Pull Back In Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Now 21% undervalued after recent price drop

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, Jun 07, 2024

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets

Now 20% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration of the People's Republic of China for the Treatment of Diabetes

A Look At The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Health Check: How Prudently Does Sihuan Pharmaceutical Holdings Group (HKG:460) Use Debt?

National Medical Products Administration Approves IND Application of Insulin Degludec and Liraglutide Injection, Developed by Huisheng Biopharmaceutical

First half 2023 earnings released: CN¥0.005 loss per share (vs CN¥0.004 profit in 1H 2022)

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2023 Results on Aug 29, 2023

Sihuan Pharmaceutical Holdings Group Ltd. Announces Huisheng Biopharmaceutical's Drug Semaglutide Injection Obtained Approval for Clinical Trial

Sihuan Pharmaceutical Holdings Group Ltd. Announces Approval of Phase II Clinical Trial Application of Birociclib by the Center for Drug Evaluation of the National Medical Products Administration of the People's Republic of China

Sihuan Pharmaceutical Holdings Group Ltd. Obtains Drug Registration Approval from the National Medical Products Administration

Upcoming dividend of HK$0.037 per share at 9.7% yield

Estimating The Fair Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Full year 2022 earnings released: CN¥0.21 loss per share (vs CN¥0.044 profit in FY 2021)

Sihuan Pharmaceutical Holdings Group Ltd. Provides Consolidated Earnings Guidance for the Year Ended 31 December 2022

Less than half of directors are independent

Is Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460) Worth HK$0.8 Based On Its Intrinsic Value?

Sihuan Pharmaceutical Holdings Group Ltd. Announces Management Changes

Does Sihuan Pharmaceutical Holdings Group (HKG:460) Have A Healthy Balance Sheet?

Upcoming dividend of HK$0.037 per share

Sihuan Pharmaceutical Holdings Group Ltd. Declares Special Cash Dividend for the Six Months Ended 30 June 2022, Payable on or Around 13 October 2022

First half 2022 earnings released: EPS: CN¥0.004 (vs CN¥0.065 in 1H 2021)

Sihuan Pharmaceutical Holdings Group Ltd. to Report First Half, 2022 Results on Aug 30, 2022

Sihuan Pharmaceutical Holdings Group Ltd. Provides Earnings Guidance for the Six Months Ended 30 June 2022

Sihuan Pharmaceutical Holdings Group Ltd. Announces Acceptance of Application for Marketing of Xuanzhu Biopharm\U0027s Drug Fulvestrant Injection by Nmpa of China

Is There An Opportunity With Sihuan Pharmaceutical Holdings Group Ltd.'s (HKG:460) 34% Undervaluation?

Upcoming dividend of HK$0.13 per share

Investor sentiment deteriorated over the past week

Less than half of directors are independent

Sihuan Pharmaceutical Obtains Class III Medical Device Registration Certificate from NMPA for Exclusively Distributed Hyaluronic Acid Persnica

Now 20% undervalued

Sihuan Pharmaceutical Holdings Group Ltd., Annual General Meeting, May 24, 2022

Full year 2021 earnings: EPS and revenues miss analyst expectations

Sihuan Pharmaceutical Holdings Group Ltd. Announces Ordinary Final Cash Dividend for the Year Ended December 31, 2021, Payable on June 14, 2022

Investor sentiment deteriorated over the past week

Now 25% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces First Class I Macromolecule Innovative Drug Her2 Bispecific Antibody Xzp-Km257 Was Approves for Clinical Trails

Estimating The Intrinsic Value Of Sihuan Pharmaceutical Holdings Group Ltd. (HKG:460)

Investor sentiment improved over the past week

National Medical Products Administration Accepts Biologics License Application of Insulin Aspart Injection, Insulin Aspart 30 Injection and Insulin Aspart 50 Injection of Jilin Huisheng Biopharmaceutical Co., Ltd

Now 22% undervalued after recent price drop

Sihuan Pharmaceutical Holdings Group Ltd. Announces Medical Device Registration Certificate Obtained for Medical Skin Care Gel and Repair Gel

Sihuan Pharmaceutical Holdings Group Ltd. Announces Fondaparinux Sodium Injection Obtained Manufacture Approval